An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

Administered By

Awarded By

Contributors

Start/End

  • September 25, 2020 - October 19, 2025